CRAD-B C-Rad AB (publ)
C-Rad AB (publ) develops, manufactures, and sells products and systems with applications in radiotherapy for the treatment of cancer in Europe, the Middle East, Africa, the Americas, and the Asia Pacific. The company offers Catalyst+ HD, a patient positioning, intra-fraction motion management, and respiratory gating solution for conventional and stereotactic treatment delivery; Catalyst+, a solution for patient set up and intra-fraction breath hold reproducibility; Catalyst+ PT, a surface image guided radiation therapy solution that supports proton therapy from simulation to treatment; Catalyst+ HD Ring Gantry solution for patient positioning, real-time motion monitoring, and respiratory gating; and Sentinel 4DCT, a laser-based optical surface scanning system. It also provides Catalyst, a 4D surface guided radiation therapy (SGRT) solution; Catalyst HD, a SGRT solution on stereotactic radiation therapy for online patient tracking before and during treatment delivery; and visual coaching solutions used for prospective and retrospective radiotherapy. In addition, the company offers cAutoVerify, an automation solution for the imaging suite and treatment room, automating patient identity validation, and accessory tracking. Further, it provides HIT1, HIT3, and HIT5 patient positioning laser, as well as laser positioning products and solutions. Additionally, the company offers support and training services; and service contracts. C-Rad AB (publ) was incorporated in 2004 and is headquartered in Uppsala, Sweden.…
Industry Peers
Medical DevicesKey Statistics
About C-Rad (STO: CRAD-B)
›
C-Rad (STO: CRAD-B) is listed on Nasdaq Stockholm, where its shares trade in SEK. It belongs to the Medical Devices industry, part of the Healthcare sector, and reports about 98 employees.
The shares were at 23.60 SEK on 19 November 2026, down 26.0% over 52 weeks. Its 52-week range is 18.85 SEK to 39.40 SEK: the price is 40.1% below the high and 25.2% above the low.
At a market capitalisation of 768.10M SEK, it trades at 16.7 times trailing earnings and 10.4 times forward earnings. The median trailing P/E of its 19 largest Medical Devices peers is 25.6, a discount of 35% for CRAD-B. It pays a dividend yielding 0.42% (it pays out 7% of its earnings), against a median of 2.36% among the dividend payers in that peer group.
C-Rad reports return on equity of 3.0%, an operating margin of 16.9% and revenue down 23.9% year over year.
It holds more cash than debt, a net cash position of 136.30M SEK. Its Piotroski F-score is 6 out of 9, an average reading of its financial health. One analyst covers the stock; their mean price target of 35.00 SEK is 48.3% above the current price.